New PET scan could reveal which kidney cancer patients respond to immunotherapy

NCT ID NCT04006522

Ongoing Knowledge-focused Sponsor: James Brugarolas Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special PET/CT scan that uses a radioactive tracer to see if it can predict how kidney cancer patients will respond to immunotherapy. The trial involves 46 participants with either localized or advanced kidney cancer. Researchers will compare scan results with actual treatment outcomes to see if the scan is a reliable predictor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-DFO-Atezolizumab (a radioactive tracer for PET/CT scans)
What this could lead to: If successful, this could lead to a better way to predict which kidney cancer patients will benefit from immunotherapy, helping doctors choose the right treatment.
What could go wrong: This is an early exploratory study with only 46 people. The scan may not accurately predict treatment response, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

UT Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.